# Fixed-time chlorazepate dipotassium premedication versus midazolam on demand: a randomised, controlled trial

| Submission date   | Recruitment status   | <ul><li>Prospectively registered</li></ul> |
|-------------------|----------------------|--|
| 13/12/2006        | No longer recruiting | ☐ Protocol                                 |
| Registration date | Overall study status | Statistical analysis plan                  |
| 13/02/2007        | Completed            | [X] Results                                |
| Last Edited       | Condition category   | Individual participant data                |
| 26/03/2021        | Surgery              |  |

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Patrick Meybohm

#### Contact details

University Hospital Schleswig-Holstein Campus Kiel Schwanenweg 21 Kiel Germany 24105

\_

meybohm@anaesthesie.uni-kiel.de

# Additional identifiers

EudraCT/CTIS number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

# Study information

#### Scientific Title

Fixed-time chlorazepate dipotassium premedication versus midazolam on demand: a randomised, controlled trial

#### Acronym

premedication

#### Study objectives

We hypothesised that:

- 1. 50 mg chlorazepate dipotassium at 10 pm evening before surgery prevent an increase of anxiety and sympatho-adrenal activity at morning of surgery sufficiently, and
- 2. A fixed-time application of chlorazepate dipotassium at 7 am morning of surgery may be superior compared to administration of midazolam 30 minutes prior to induction of anesthesia with respect to level of anxiety, sympatho-adrenal activity and conscious sedation.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

The trial was approved by the local ethics committee of the University Kiel on the 3rd April 2002 (reference number: AZ 142/01).

## Study design

Randomised double-blind placebo-controlled study

# Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Hospital

# Study type(s)

Treatment

#### Participant information sheet

# Health condition(s) or problem(s) studied

Premedication, Anaesthesia

#### **Interventions**

Patients were randomised to one of two groups:

1. Group CCP: at Evening Before Surgery (EBS) clorazepate dipotassium 50 mg orally (Tranxilium®; Sanofi-Aventis GmbH, Frankfurt am Main, Germany); at Morning Of Surgery (MOS)

clorazepate dipotassium 25 mg orally; and before Induction of Anesthesia (AI) placebo orally 2. Group CPM: at EBS clorazepate dipotassium 50 mg orally; at MOS placebo orally; before AI midazolam 7.5 mg orally (Dormicum®; Roche, Mijdrecht, The Netherlands)

Dosages of clorazepate dipotassium in our study were based on recommendations that have been published previously.

#### Intervention Type

Drug

#### **Phase**

**Not Specified** 

## Drug/device/biological/vaccine name(s)

Chlorazepate dipotassium and midazolam

#### Primary outcome measure

- 1. Level of anxiety
- 2. Sympatho-adrenal activity (plasma levels of Adrenocorticotropic Hormone [ACTH], cortisol, norepinephrine and epinephrine)

## Secondary outcome measures

- 1. Haemodynamic data
- 2. Oxygen saturation
- 3. Conscious sedation
- 4. Bispectral index

#### Overall study start date

01/05/2003

#### Completion date

01/10/2004

# **Eligibility**

#### Key inclusion criteria

- 1. Patients with an American Society of Anaesthesiologists (ASA) physical status of one or two
- 2. Aged between 18 and 55 years
- 3. Weighing from 60 to 88 kg
- 4. Scheduled to undergo an elective surgical, orthopaedic or urologic procedure in general anesthesia

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Lower age limit

18 Years

#### Sex

**Not Specified** 

# Target number of participants

50

#### Total final enrolment

50

#### Key exclusion criteria

- 1. Sleep apnoea syndrome
- 2. Pregnancy
- 3. Use of sedative, stimulant, or other medications within the previous month
- 4. The presence of neurological, renal, or hepatic disease

#### Date of first enrolment

01/05/2003

#### Date of final enrolment

01/10/2004

# Locations

#### Countries of recruitment

Germany

# Study participating centre University Hospital Schleswig-Holstein

Kiel Germany 24105

# Sponsor information

#### Organisation

University Hospital Schleswig-Holstein (Germany)

#### Sponsor details

24105

Campus Kiel Department of Anaesthesiology and Intensive Care Medicine Schwanenweg 21 Kiel Germany

#### Sponsor type

Hospital/treatment centre

#### **ROR**

https://ror.org/01tvm6f46

# Funder(s)

# Funder type

Hospital/treatment centre

#### **Funder Name**

University Hospital Schleswig-Holstein (Germany)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

| Output type     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-----------------|---------|--------------|------------|----------------|-----------------|
| Results article |         | 01/09/2007   | 26/03/2021 | Yes            | No              |